Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When a medical device manufacturer, particularly one based outside the European Union, needs to appoint a regulatory representative, what are the critical factors to assess beyond basic compliance? Wh...
For non-EU developers of AI-enabled medical technology, navigating European representation requirements is becoming increasingly complex. The GDPR's mandate for an Article 27 Representative is well-es...
For non-EU manufacturers of AI-enabled medical devices or SaMD, the upcoming EU AI Act introduces a new layer of complexity on top of existing GDPR obligations. While GDPR Article 27 requires a repres...
For non-EU providers of AI systems, particularly those classified as high-risk under the EU AI Act, appointing an EU Authorized Representative (AR) is a critical compliance step. While specific fees a...
With the introduction of the EU AI Act, non-EU providers of AI systems, particularly those classified as high-risk, face the new obligation of appointing an EU-based Authorized Representative (AR). Be...
For foreign medical device establishments planning for U.S. market entry, understanding the full scope of associated costs is critical. While FDA user fees, such as those for establishment registratio...
With various regulatory deadlines and user fee schedules being updated, many foreign medical device establishments are asking: what are the FDA requirements for a U.S. Agent in 2026, and are any signi...
As medical devices become increasingly interconnected, how can sponsors effectively integrate cybersecurity management into their existing Quality Management System (QMS) to align with evolving regula...
With significant updates to EU cosmetic regulations anticipated for 2026, including changes related to the CLP Regulation and INCI nomenclature, how should a non-EU brand structure its evaluation proc...
For a non-EU company launching an AI-powered Software as a Medical Device (SaMD) in Europe, how can it strategically select a GDPR Article 27 Representative that is truly fit for purpose in a complex ...
For a non-EU manufacturer of an AI-enabled medical device, appointing an in-region representative is a critical step for market entry. However, with the convergence of medical device regulations, stri...
With the introduction of new EU regulations like the Packaging and Packaging Waste Regulation (PPWR), how should economic operators, including medical device manufacturers, evolve their criteria for s...
While non-EU manufacturers often budget for an EU Authorized Representative (AR) under medical device regulations, the introduction of the Carbon Border Adjustment Mechanism (CBAM) adds a new layer of...
When preparing a premarket submission for a connected medical device, such as a Class II Software as a Medical Device (SaMD) or a networked patient monitor, how can sponsors effectively demonstrate co...
With the implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), foreign cosmetic facilities marketing products in the United States must now designate a U.S. Agent. This requ...
When a small or medium-sized enterprise (SME) seeks to contract a "Person Responsible for Regulatory Compliance (PRRC) as a Service" to meet EU MDR Article 15 requirements, how can the organization mo...
As medical device manufacturers plan their budgets for 2025, securing a Person Responsible for Regulatory Compliance (PRRC) remains a critical requirement under the EU MDR, particularly for companies ...
As the EU AI Act creates new compliance obligations alongside the GDPR and MDR/IVDR, how should manufacturers of AI-enabled medical devices and Software as a Medical Device (SaMD) approach the selecti...
For AI companies based outside the EU that process the personal data of individuals within the Union, appointing a representative under GDPR Article 27 is a fundamental compliance requirement. As the ...
With the EU AI Act establishing new requirements for non-EU providers of high-risk AI systems, selecting an EU Authorized Representative (AR) becomes a critical compliance step. Beyond simply having a...